Trial reportArthritis research & therapy2010
Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.
Trial report in Arthritis research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Etanercept on the Early Clinical Course of Polymyalgia Rheumatica (Pilot Study)
A Multicenter Randomized Placebo Controlled Treatment Study of Leflunomide in Polymyalgia Rheumatica
Is the Melanocortin System Involved in Inflammatory Resolution
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review.Rheumatology (Oxford, England) · 2024Pooled it
- Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review.Rheumatology international · 2016Pooled it
- Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV-154 in Adults With Glucocorticoid-Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment.BMC musculoskeletal disorders · 2017Trial
- Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment.Arthritis research & therapy · 2012Trial
- Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.Nature reviews. Rheumatology · 2026Review
- Modern Management of Isolated Polymyalgia Rheumatica.Rheumatology and therapy · 2025Review
- Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with Polymyalgia Rheumatica: a narrative review.BMC rheumatology · 2024Article
- Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.Journal of clinical medicine · 2024Review
- Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study.Rheumatology and therapy · 2024Article
- [Methods for assessment of disease activity of polymyalgia rheumatica].Zeitschrift fur Rheumatologie · 2023Review
- Case Report and Literature Review of an Atypical Polymyalgia Rheumatica and Its Management.International medical case reports journal · 2023Article
- An update on polymyalgia rheumatica.Journal of internal medicine · 2022Review
- The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios.Journal of personalized medicine · 2022Article
- Reply to: What could a new disease activity score for polymyalgia rheumatica do better?Nature reviews. Rheumatology · 2021Article
- Anti-Rheumatic Effect of Antisense Oligonucleotide Cytos-11 Targeting TNF-α Expression.International journal of molecular sciences · 2021Article
- Polymyalgia Rheumatica: a Common Disease in Seniors.Current rheumatology reports · 2020Review
- Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.Drugs & aging · 2019Review
- Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.Nature reviews. Rheumatology · 2017Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo elucidate in polymyalgia rheumatica (PMR) the role of tumor necrosis factor (TNF) α and the therapeutic potential of blockade with soluble TNF-α receptor, we carried out the first randomized controlled trial with etanercept in PMR.
methodsTwenty newly diagnosed, glucocorticoid (GC) naïve patients with PMR and 20 matched non-PMR control subjects completed the trial. Subjects were randomized in a 1:1 ratio to monotherapy with etanercept (25 mg s.c. biweekly) or placebo (saline) for 14 days. Study outcomes were assessed at baseline and after 14 days. The primary outcome was the change in PMR activity score (PMR-AS). Secondary outcomes were: changes in erythrocyte sedimentation rate (ESR) and plasma levels of TNF-α and interleukin (IL) 6; patients' functional status (health assessment questionnaire) and cumulative tramadol intake during the trial.
resultsAt baseline, plasma TNF-α was higher in patients than in controls (P < 0.05). The concentration always increased with etanercept treatment (P < 0.05). In patients, etanercept decreased PMR-AS by 24% (P = 0.011), reflecting significant improvements in shoulder mobility, physician's global assessment and C-reactive protein, and insignificant (P > 0.05) improvements in duration of morning stiffness and patient's assessment of pain. In parallel, ESR and IL-6 were reduced (P < 0.05). Placebo treatment did not change PMR-AS, ESR and IL-6 (P > 0.05). Functional status did not change and tramadol intake did not differ between patient groups. In controls, no changes occurred in both groups.
conclusionsEtanercept monotherapy ameliorates disease activity in GC naïve patients with PMR. However, the effect is modest, indicating a minor role of TNF-α in PMR.
trial registrationClinicalTrials.gov (NCT00524381).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.